Recent Advances in the Study of Benzoic Acid,2-hydroxy-4-methoxy-3-(3-methyl-2-butenyl)-6-[(1E)-2-phenylethenyl]- (CAS: 87402-84-4)
The compound Benzoic acid,2-hydroxy-4-methoxy-3-(3-methyl-2-butenyl)-6-[(1E)-2-phenylethenyl]-, with the CAS number 87402-84-4, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, including a hydroxy-methoxy benzoic acid core and a prenyl-styryl side chain, has shown promising biological activities. Recent studies have focused on its potential applications in drug development, particularly in the areas of anti-inflammatory, anticancer, and antimicrobial therapies.
One of the key findings from recent research is the compound's ability to modulate inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 87402-84-4 effectively inhibits the NF-κB signaling pathway, which plays a critical role in inflammation and immune responses. The study utilized in vitro models of human macrophages and in vivo murine models of inflammation, showing significant reduction in pro-inflammatory cytokines such as TNF-α and IL-6. These results suggest that the compound could be a potential candidate for developing novel anti-inflammatory drugs.
In addition to its anti-inflammatory properties, 87402-84-4 has also been investigated for its anticancer potential. A recent study in Bioorganic & Medicinal Chemistry Letters explored the compound's effects on various cancer cell lines, including breast, lung, and colon cancers. The research highlighted that the compound induces apoptosis in cancer cells through the activation of caspase-3 and PARP cleavage. Furthermore, molecular docking studies revealed that 87402-84-4 interacts with key oncogenic targets, such as EGFR and PI3K, suggesting a multi-targeted mechanism of action. These findings open new avenues for the development of targeted cancer therapies.
Another area of interest is the antimicrobial activity of 87402-84-4. A 2024 study published in Antimicrobial Agents and Chemotherapy reported that the compound exhibits broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The study also identified that the compound disrupts bacterial cell membrane integrity, leading to cell lysis. Given the rising threat of antibiotic resistance, these findings are particularly relevant and could contribute to the development of new antimicrobial agents.
Despite these promising results, challenges remain in the clinical translation of 87402-84-4. Pharmacokinetic studies indicate that the compound has limited bioavailability, which may hinder its therapeutic efficacy. Recent efforts have focused on structural modifications and formulation strategies to improve its solubility and stability. For instance, a 2023 patent application described the synthesis of prodrug derivatives of 87402-84-4, which showed enhanced oral bioavailability in preclinical models. These advancements are critical for moving the compound from bench to bedside.
In conclusion, the latest research on Benzoic acid,2-hydroxy-4-methoxy-3-(3-methyl-2-butenyl)-6-[(1E)-2-phenylethenyl]- (CAS: 87402-84-4) underscores its potential as a multi-functional therapeutic agent. Its anti-inflammatory, anticancer, and antimicrobial properties make it a valuable candidate for further drug development. However, addressing its pharmacokinetic limitations will be essential for its successful clinical application. Future studies should focus on optimizing its chemical structure and exploring synergistic effects with existing drugs to maximize its therapeutic potential.
![Benzoic acid,2-hydroxy-4-methoxy-3-(3-methyl-2-butenyl)-6-[(1E)-2-phenylethenyl]- structure](https://ossimg.kuujia.com/scimg/87500/87402-84-4x500.png)
